Innovodigm

Innovodigm is a pioneering medtech company specializing in advanced vaccine and biologics delivery solutions. Its core focus is on developing micro-array patches (MAPs) that enable painless, needle-free administration of vaccines, addressing key challenges in global immunization such as cold-chain dependency, medical waste and needle-stick injuries. The company’s flagship product, Theroptach, is designed to be thermostable, maintaining vaccine viability for up to 120 days at 40°C, which significantly enhances vaccine accessibility in remote and underserved regions.

Core Products and Services

• Microneedle Patch Platform: Patches for transdermal vaccine and biologic delivery.

• Technology Development: Proprietary microneedle design for enhanced efficacy and patient comfort.

• Custom Solutions: Tailored patch development for specific vaccine or biologic needs.

Business Model & Revenue Streams

• Revenue Generation: Primarily through product sales and licensing of microneedle technology to pharmaceutical and biotech partners (reflecting recent market trends).

• Business Unit/Geography Contribution: Early stage; revenue primarily from India, with expansion plans into global markets (no detailed percentage splits available yet).

• Customer Segmentation: B2B focus—serving pharmaceutical companies and public health organizations; minimal direct B2C exposure.

Top Clients & Partnerships

• Key Partners: Collaborations with vaccine manufacturers and research organizations; seed funding led by IAN Group.

• Marquee Contracts: No public disclosure of major long-term contracts yet; focus on R&D partnerships and pilot projects.

• Client Concentration & Diversification: Early stage with limited client base; actively seeking to diversify through new partnerships and technology licensing.

Future Outlook & Strategic Priorities

• Growth Drivers: Expansion into global markets, development of new vaccine and biologic patches and strategic M&A or licensing opportunities.

• Risks & Headwinds: Regulatory hurdles in medical device approvals, competition from established needle-based vaccine delivery and technological disruption from new entrants.

• Management Targets: Focus on securing regulatory approvals, scaling production, and expanding partnerships; capital allocation towards R&D and market expansion.